Five million Americans currently have Alzheimer’s disease (AD); left unchecked, that number will balloon to 16 million by 2050. Given the debilitating nature of the disease, research has turned its focus to the prevention and early treatment of cognitive and behavioral symptoms.
A new paper from a group of Alzheimer’s experts outlines what’s needed to meet the federal government’s goal of effective prevention or treatment by 2025. Lead author Jeffrey Cummings, MD, ScD, gives the lowdown.
Agitation is a common and hard-to-treat behavior change in Alzheimer disease. But recent trials of two existing agents suggest there’s hope for effective therapy without the need to resort to antipsychotics.
The Lou Ruvo Center for Brain Health is working to transform the clinical trial process for Alzheimer disease. It is committed to focusing on the right patients, the right drugs and the right outcomes.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
A breakthrough in the quest for a disease-modifying AD therapy is long overdue. Cleveland Clinic has developed a large, diverse and multisite clinical trials program in response. Here’s what drives our approach.
The FDA-approved lymphoma therapy bexarotene reduces brain amyloid in a mouse model of Alzheimer disease (AD). The BEAT-AD study is now studying it for the first time in humans with AD.